What is CBG? The mother of cannabinoids – effects, receptors, dosing 2026

If you are looking for an answer to the question of what CBG is, you are encountering one of the most underrated cannabis cannabinoids. Cannabigerol (CBG) typically constitutes less than 1 percent of the cannabinoid mass in a mature cannabis plant, yet it is the biochemical precursor to virtually all other cannabinoids, including CBD, THC, and CBC (Calapai et al., Medicina, 2022). The CBG market in Europe is growing at a CAGR of 16.2 percent (Fortune Business Insights, 2024), and the reason is simple. CBG directly binds to CB1 and CB2 receptors as a partial agonist, activates the alpha-2 adrenergic receptor, and shows promising data in chronic inflammation, bacterial resistance, and intestinal pathologies.

In this guide, we explain what CBG is from a biochemical perspective, how its receptor profile differs from CBD, what the current clinical and preclinical evidence is, what realistic sublingual doses look like, what Polish and European law says, and when to reach for CBG oil instead of CBD. Without marketing simplifications, with references to PubMed, PMC, the British Journal of Pharmacology, and Cannabis and Cannabinoid Research.

KEY INFORMATION

• The Mother of Cannabinoids: CBGA is the biochemical precursor to CBDA, THCA, and CBCA; without CBGA, no other plant cannabinoids are produced (Calapai et al., Medicina, 2022).
• Receptor Profile: CB1 and CB2 as a partial agonist, strong activity on alpha-2 adrenergic, antagonism of 5-HT1A (Cascio et al., British Journal of Pharmacology 2010).
• Sublingual Dosage: start with 10-15 mg daily, aiming for 25-50 mg in two doses, titrating every 5-7 days.
• Strongest Evidence: antibacterial action against MRSA (Farha et al., 2020), reduction of intestinal inflammation (Borrelli et al., 2013), lowering of intraocular pressure (Colasanti, 1990).
• Legality: CBG is permitted in Poland and the EU; products must have THC below 0.3 percent and a COA certificate.

What is CBG from the perspective of cannabis plant biochemistry?

CBG is a non-psychoactive phytocannabinoid that is produced first in the cannabinoid biosynthesis pathway in the trichomes of the cannabis plant. In its acidic form (CBGA), it serves as a precursor for three main enzymatic pathways: THCA synthase, CBDA synthase, and CBCA synthase (Calapai et al., Medicina, 2022). In a mature plant, CBG usually remains below 1 percent of its mass, which is why strains specifically cultivated for its extraction are harvested earlier.

The full chemical name of CBG is cannabigerol, and its molecular formula is C21H32O2. Its structure has an open geranyl chain, which distinguishes it from CBD with a closed pyran ring. This slight structural distinction explains CBG's greater lipophilicity and its stronger affinity for the alpha-2 adrenergic receptor. In plant synthesis, synthase enzymes are selective: the same CBGA can be converted into THCA in a marijuana strain or into CBDA in a hemp strain.

The biochemical specificity of CBG explains its rarity. Cannabis strains selected over the last two decades for high CBD or THC content had minimal CBG concentration, as most CBGA was consumed by synthase enzymes. In 2019, the University of Guelph (Canada) introduced lines with 10-15 percent CBG, thanks to the genetic 'knockout' of THCA and CBDA synthases. The commercial CBG market only accelerated after this breeding change.

Why is CBG called the mother of cannabinoids?

The term 'mother of cannabinoids' comes from the fact that CBGA is a common substrate from which other cannabinoid acids are formed. Without CBGA, there is no CBDA, THCA, or CBCA. After thermal decarboxylation, all these acids lose their carboxyl group and transform into active neutral forms: CBD, THC, and CBC. This explains why CBGA is unique in the context of cannabinoid biosynthesis.

In practice, the significance of CBG's maternal role goes beyond biology. For the oil producer, this means that the harvest must occur before the synthase enzymes consume CBGA. For the consumer, it means that CBG oils are more expensive because the raw material must be sourced faster, and the yield is lower. The cost of producing CBG oil is 2-3 times higher than that of CBD oil of the same potency.

Chemical Structure and Physicochemical Properties

CBG has a molar mass of 316.48 g/mol and is highly lipophilic (logP ≈ 6.1). This means it dissolves in fats, not in water. At room temperature, it is a thick, light yellow oil with a delicate grassy aroma. The boiling point is 257 degrees Celsius, which is significant when vaporizing cannabis flower rich in CBG.

Like CBD and THC, CBG is sensitive to UV light and oxygen. Therefore, high-quality oils are packaged in dark glass bottles and stored in a cool place. Exposure to heat above 60 degrees accelerates oxidative degradation, which affects the product's effectiveness after opening.

How does CBG interact with CB1, CB2, and alpha-2 receptors?

CBG acts as a partial agonist of CB1 and CB2 receptors and a strong modulator of the alpha-2 adrenergic receptor (Cascio et al., British Journal of Pharmacology, 2010). This fundamentally distinguishes it from CBD, which shows minimal direct affinity for CB1 and CB2, and primarily acts through the 5-HT1A receptor and inhibition of the FAAH enzyme. In the endocannabinoid system, CBG thus occupies a unique position.

The CB1 receptor is mainly located in the central nervous system, in the cerebral cortex, hippocampus, and cerebellum. Activation of CB1 is responsible for the psychoactive effect of THC. However, CBG, as a partial agonist of CB1, does not produce a high because its intrinsic activity is very low. In the presence of THC, CBG even antagonizes its psychoactive effect, as confirmed by Cascio's 2010 study. Therefore, CBG oils do not cause perceptual disturbances.

The CB2 receptor is mainly found in immune cells, the intestines, and the skin. Activation of CB2 has anti-inflammatory, analgesic, and immunomodulatory effects. CBG, as a partial agonist of CB2, explains its anti-inflammatory action in models of IBD, acne, and inflammatory joint conditions. This is a complementary mechanism to CBD's action on the same receptor.

The alpha-2 adrenergic receptor, a unique feature of CBG

The alpha-2 adrenergic receptor is located at the presynaptic endings of noradrenergic neurons. Its activation reduces the release of norepinephrine, leading to lower blood pressure, relaxation of smooth muscles, and decreased intraocular pressure. This is the same mechanism used by brimonidine drops used in glaucoma.

The affinity of CBG for the alpha-2 adrenergic receptor is significantly higher than that of CBD. The Ki value is around 0.2 micromoles for CBG compared to over 10 micromoles for CBD. This difference explains why CBG exhibits more pronounced effects on concentration, muscle tension, and intraocular pressure. It is not a 'stronger' effect, but rather a different pharmacological mechanism.

Modulation of the 5-HT1A receptor and other targets

CBG additionally interacts with the serotonin receptor 5-HT1A, but unlike CBD, it acts as an antagonist rather than an agonist. This has significant consequences. CBD increases serotonergic transmission (anxiolytic effect), while CBG may weaken it at high doses. For this reason, CBG at higher doses may induce a state of agitation rather than sedation.

CBG also affects vanilloid receptors TRPV1 and TRPV2 (pain and temperature receptors), TRPA1 receptors, and PPAR-gamma. Activation of PPAR-gamma has anti-inflammatory, metabolic, and neuroprotective effects. This broad map of molecular targets explains why CBG exhibits activity in such diverse disease models, from glaucoma to inflammatory bowel disease.

Unique observation: While CBD is a 'modulating molecule' (altering the action of existing neurotransmitters), CBG is a 'direct-acting molecule' on cannabinoid receptors. This mechanistic difference means that CBG may be more predictable in its effects than CBD, but at the same time more sensitive to dosage. A dose that is too high of CBG can cause stimulation instead of calming, which is not observed with CBD.

In the receptor study by Cascio et al. (2010), CBG showed a Ki affinity of 0.2 micromoles for the alpha-2 adrenergic receptor, a value comparable to clinically used brimonidine, while its activity at the CB1 receptor was about 100 times weaker than that of THC (British Journal of Pharmacology, 2010). This confirms that CBG does not produce a psychoactive effect.

What are the strongest therapeutic evidences for CBG?

The best-documented actions of CBG are its antibacterial effect on resistant strains (MRSA), reduction of intestinal inflammation in animal models, and lowering of intraocular pressure. In the study by Farha et al. (ACS Infectious Diseases, 2020), CBG inhibited the growth of MRSA at concentrations comparable to vancomycin. This is the strongest preclinical data for this cannabinoid.

The study by Borrelli et al. (Biochemical Pharmacology, 2013) showed that CBG reduces colitis in a mouse model of DNBS by about 50 percent. The mechanism involves inhibition of iNOS synthase, reduction of IL-1beta, and modulation of CB2. This is the foundation for further research on the application of CBG in human inflammatory bowel disease.

The work of Colasanti (Journal of Ocular Pharmacology, 1990) demonstrated that locally administered CBG lowers intraocular pressure in rabbits. The mechanism is based on the activation of the alpha-2 receptor, similar to clinically used brimonidine. This is an old but still cited evidence of CBG's potential in ophthalmology.

Antibacterial action against resistant strains

In the 2020 study by Farha, CBG was tested against 96 strains of gram-positive and gram-negative bacteria. It showed the best activity against MRSA, with a minimum inhibitory concentration (MIC) of 2 micrograms/ml. For comparison, the MIC of vancomycin against MRSA is 1-2 micrograms/ml, indicating comparable potency in vitro.

A unique feature of CBG is its ability to disrupt bacterial biofilm. A biofilm is a protective structure that bacteria produce on surfaces (implants, catheters, wounds). Classic antibiotics struggle to penetrate biofilms. CBG in Farha's study disrupted MRSA biofilm at concentrations that did not kill free bacteria. This is a new direction for potential therapy.

In a mouse model of MRSA infection, systemically administered CBG reduced the bacterial load by 2-3 orders of magnitude compared to the control group. This provides a basis for considering CBG as a complement to classic antibiotic therapy, especially in skin and soft tissue infections. However, clinical studies in humans are necessary before any therapeutic application.

Potential in inflammatory bowel disease (IBD)

The work of Borrelli from 2013 is the most cited evidence of CBG's action in IBD. In a mouse model of DNBS-induced colitis, CBG at a dose of 1-30 mg/kg body weight reduced inflammatory markers by 40-60 percent. The most important effects include a decrease in myeloperoxidase (MPO), reduction of IL-1beta, and decreased histological damage to the mucosa.

Importantly, CBG acted effectively without causing significant side effects in animals. This contrasts with classic IBD therapy (steroids, immunosuppression), which has numerous adverse effects. CBG may in the future be part of adjunctive therapy, but we need randomized studies in humans with Crohn's disease and ulcerative colitis.

Glaucoma, IBD, and neuroprotection: what do we know now

In glaucoma, CBG showed potential in Colasanti's 1990 study and subsequent replications. A reduction in intraocular pressure of 20-30 percent after local administration of CBG is comparable to clinically used brimonidine. However, there is a lack of randomized trials in humans, so CBG does not replace any registered glaucoma therapy. This is a direction for future research.

In neurodegenerative diseases, CBG exhibits neuroprotective effects in Huntington's disease models (Valdeolivas et al., Neurotherapeutics, 2015). It protects striatal neurons from the toxicity of 3-nitropropionic acid. Similar effects have been observed in models of amyotrophic lateral sclerosis (ALS) and Parkinson's disease. This is early science, but it opens new research fields.

In metabolism, CBG may increase appetite without a psychoactive effect, which distinguishes it from THC. A 2016 study on rats showed that CBG at a dose of 120-240 mg/kg increased food intake by 28 percent. This is a potential therapeutic direction for patients with oncological cachexia and geriatric anorexia.

In the study by Farha et al. (ACS Infectious Diseases 2020), CBG inhibited the growth of MRSA at an MIC of 2 micrograms/ml, a value comparable to vancomycin, and disrupted bacterial biofilm at non-bactericidal concentrations, indicating a unique two-step action mechanism (ACS Infectious Diseases, 2020). This opens the way for research on CBG as an adjunct to antibiotic therapy for resistant infections.

How does CBG differ from CBD in practice?

Although CBG and CBD have the same molecular formula C21H30O2 in their neutral form, their geometry, receptor profile, and subjective effect are distinctly different. Both are non-psychoactive, but 51 percent of CBG users in a 2021 survey reported improved concentration, while 66 percent of CBD users reported improved sleep (Cannabis and Cannabinoid Research, 2021).

CBD primarily acts indirectly: it modulates the serotonin receptor 5-HT1A (anxiolytic effect), inhibits the FAAH enzyme (increases anandamide levels), and activates TRPV1 receptors (analgesic effect). Direct affinity for CB1 and CB2 is minimal. This explains why CBD at higher doses (300 mg and more) has anxiolytic and anticonvulsant effects.

CBG acts directly: it activates CB1 and CB2 as a partial agonist, strongly binds to alpha-2 adrenergic, and influences TRPV1 and PPAR-gamma. The subjective effect is more 'focus without drowsiness' than 'relaxation'. Therefore, CBG is gaining popularity among mentally active individuals, athletes needing muscle relaxation, and patients with digestive disorders.

Differences in availability and market price

CBD is significantly cheaper to produce because hemp plants contain 10-20 percent of their mass in CBD. A 10 percent CBD oil in Poland costs 90-150 PLN for 10 ml. CBG occurs naturally in amounts below 1 percent, making extraction 10-20 times more difficult. Therefore, a 10-15 percent CBG oil costs 200-300 PLN for 10 ml. The price difference arises from raw material difficulty, not from greater efficacy.

In 2024, the availability of CBG in Poland significantly increased. 'CBG-dominant' strains with 10-15 percent CBG appeared in major extraction facilities in the EU. This reduced the unit cost by about 30 percent compared to 2022. Further price declines are expected as CBG-dominant genetics become standard in hemp cultivation.Hemp Facts, 2024).

When to choose CBG and when to choose CBD?

CBG makes sense if you are looking for: improved concentration without drowsiness, muscle relaxation, support for gut health, potential local antibacterial action, or a 'morning' cannabinoid profile. CBG oil 10-15 percent in doses of 15-30 mg in the morning works well for mentally active individuals, programmers, writers, and managers.

CBD makes sense if you are looking for: sleep support, anxiety and stress reduction, improved recovery after exercise, anti-inflammatory action on the skin. A broad-spectrum 5-10 percent CBD oil in doses of 20-50 mg daily is the most common protocol. CBD is also a better choice for individuals with clinical anxiety, as it has more RCT data in humans.

The most common solution is a combination. Broad-spectrum CBD oil in the morning and evening, plus 15 percent CBG oil around 8-10 AM for 'focus'. This configuration utilizes the entourage effect, covers the entire day, and provides flexibility. A 2023 Project CBD study shows that 62 percent of regular users choose a combination of different cannabinoids.Project CBD, 2023).

From the Bucha editorial office: In the last 18 months, we have observed that customers most frequently ask about CBG in two contexts: 'I can't focus at work' and 'I have gut issues, CBD is not enough'. These are clearly different profiles than classic inquiries about CBD ('I can't sleep, I'm stressed'). Therefore, in the store categorization, we have separated CBG as a distinct segment, not as a subcategory of CBD. This decision reflects real consumer behavior.

How to properly dose CBG sublingually?

Reasonable dosing of CBG starts at 10-15 mg daily and ends in the range of 25-50 mg for most users. An observational study by Russo et al. (Cannabis and Cannabinoid Research 2022) showed that the average effective dose among regular CBG users is 28 mg daily, most often divided into two doses. Higher doses (above 100 mg) were used in animal models and are not routinely recommended for humans.

The principle of 'start low, go slow' applies to CBG even more strongly than to CBD. CBG has a different dose-response profile: too high a dose can cause stimulation, anxiety, or increased blood pressure due to antagonism at 5-HT1A. Therefore, a reasonable protocol looks like this: 10 mg once daily for 5-7 days, then 10 mg in the morning and 10 mg at noon for another 5-7 days, ultimately aiming for 15-20 mg twice daily.

The sublingual form is the gold standard. Hold CBG oil drops under your tongue for 60-90 seconds before swallowing. This bypasses first-pass metabolism and provides a bioavailability of 13-19 percent, compared to 6-10 percent for capsules and gummies. The effect appears in 15-45 minutes, peaks after 60-90 minutes, and the overall duration of action is 4-6 hours.

How to convert drops to milligrams?

A standard drop of oil has a volume of about 0.05 ml. At a concentration of 5 percent CBG oil, one drop contains about 2.5 mg of CBG. At 10 percent, it is about 5 mg, and at 15 percent, it is about 7.5 mg. To achieve a dose of 15 mg of CBG, you need 6 drops of 5 percent oil, 3 drops of 10 percent oil, or 2 drops of 15 percent oil.

In practice, the choice of concentration depends on the target dose and convenience. For starting doses of 10-15 mg daily, 5 percent CBG oil is sufficient. For advanced users (25-50 mg daily), 10 or 15 percent oil works better, as a smaller drop volume means less burden on the palate and faster sublingual absorption.

Combining CBG with CBD in one protocol

The most common combination is broad-spectrum 5-10 percent CBD oil as a daily base, plus 15 percent CBG oil as a morning addition. Doses: 20-40 mg of CBD total per day, plus 15-20 mg of CBG in the morning. This configuration covers the effects of both cannabinoids without overlapping their actions in an unfavorable way. CBD provides baseline relaxation and anti-inflammatory action, while CBG adds focus and digestive support.

There is also an alternative: full-spectrum oil, which naturally contains CBD, CBG, CBC, CBN, and terpenes. Such oil has an entourage effect without the need to combine two products. The downside is the lack of precise control over CBG dosage, as the cannabinoid ratios in full-spectrum are 'naturally' variable depending on the cannabis strain and batch.

Interactions with medications, CYP450

Like CBD, CBG inhibits cytochrome P450 enzymes, mainly CYP3A4 and CYP2C9. This means it may affect the metabolism of many medications, including warfarin, statins, antiepileptics, some antidepressants, and calcineurin inhibitors (PMC, 2019). If you are taking medications metabolized by CYP3A4, consult your doctor or pharmacist before starting CBG supplementation.

Practical rule: separate the intake of CBG and medications in time. Take the cannabinoid at least 2 hours before or after the medication. This does not eliminate interactions but reduces them. Monitor the therapeutic effects of medications (e.g., INR in patients on warfarin, levels of antiepileptic drugs) and report any changes in their effects to your doctor after introducing CBG.

Particular caution with: warfarin and other anticoagulants (risk of bleeding), antiepileptic medications (clobazam, valproate), immunosuppressants after transplants (tacrolimus, cyclosporine). Absolutely do not combine CBG with medications without the knowledge of your treating physician if you are on chronic therapy.

What is the legal status of CBG in Poland and the EU in 2026?

CBG is not listed on the Polish controlled substances list nor on EU narcotic lists, and its content in products is not restricted (Journal of Laws 2005 No. 179 item 1485). The legality of CBG oil depends solely on the THC content, which must be below 0.3 percent according to EU regulation 2021/2115 on hemp.

In Poland, CBG products are mainly sold as cosmetics (for topical use) or 'for collector's purposes'. They are not registered as dietary supplements or medicines. This is due to the EU status of cannabinoids as 'novel food', which has been lacking EFSA authorization since 2019. The procedure is ongoing, but in the current state, producers must adjust their labeling.

Like CBD, CBG is legal in other EU countries, although with local nuances. In France, until 2022, there were restrictions on the cannabinoid list, but after the EU Court ruling on Kanavape, producers received full freedom to trade CBD and CBG throughout the Union, provided they comply with the THC limit of 0.3 percent. In Germany and the Netherlands, CBG has a status similar to that in Poland.

What is allowed and what is not in marketing communication

It is allowed: to describe CBG products as supporting wellness, relaxation, concentration, digestive comfort (using 'support' language, not 'treatment'). It is allowed: to publish chemical composition, scientific studies, and laboratory data. It is allowed: to sell in physical stores and online. It is allowed: to transport in carry-on luggage within the country and in EU countries with a similar THC limit.

It is not allowed: to present CBG products as medicines or use medical claims ('cures IBD', 'heals glaucoma'). It is not allowed: to sell products with THC above 0.3 percent. It is not allowed: to transport CBG to countries with strict drug laws (e.g., Hong Kong, United Arab Emirates, Japan) without prior verification of regulations.

COA Certificates and Trusted Supplier

A Certificate of Analysis (COA) from an independent laboratory is an absolute standard when purchasing CBG oil. The COA should include: cannabinoid analysis (CBD, CBG, CBN, CBC, THC), analysis of heavy metals, pesticides, residual solvents, and microbiology. Without a COA, you do not know what you are really buying. Manufacturers without a COA are a warning sign.

In the u Bucha store, every CBG oil has a COA available for review on the product page or upon request. This is a standard we have built over 5 years of operation. If a manufacturer does not want to provide a COA, that is the best reason to refrain from purchasing. There are still products on the market with CBG content significantly lower than declared on the label.

Bucha data Q1 2026: In our CBG oil category, 78 percent of orders concern concentrations of 10-15 percent, 15 percent of customers choose 5 percent as a start, and only 7 percent opt for higher concentrations above 15 percent. The average order value for CBG is 185 PLN, compared to 120 PLN for CBD. CBG customers are more loyal, with 64 percent returning for a repeat purchase within 60 days, compared to 48 percent for CBD.

Why is CBG more expensive than CBD?

The price of 10-15 percent CBG oil is on average 2-3 times higher than that of 10 percent CBD oil, mainly due to the low content of CBG in the plant (usually below 1 percent) and higher extraction costs. A 15 percent CBG oil costs about 240 PLN for 10 ml in Poland, while a 10 percent CBD oil can be purchased for 99 PLN (Hemp Facts, 2024). The price difference reflects raw material difficulty, not therapeutic value.

CBG extraction requires precise timing of the harvest. The plant must be cut before the synthase enzymes consume CBGA. This means an earlier harvest (3-4 weeks before full maturity) and lower biomass yield per hectare. Therefore, CBG yields from classic strains are 50-70 percent lower than CBD yields. CBG-dominant strains allow for harvesting at the normal time, but the genetics themselves are more expensive to license.

By 2024, the CBG market in Europe was dominated by a few producers. Competition was limited, which kept margins high. Currently, with the emergence of more CBG-dominant strains and extractors specializing in this cannabinoid, prices are starting to fall. We anticipate a gradual convergence of CBG prices to CBD over the next 3-5 years, but never a full equalization.

What affects the quality of CBG oil?

Key factors: 1) source of raw material (organic hemp vs conventional), 2) extraction method (supercritical CO2 vs ethanol vs petrochemical), 3) product purification (short-path distillation, chromatography), 4) carrier oil (MCT from coconut vs hemp oil vs grape seed oil), 5) storage and packaging (amber glass, cool place).

The highest quality comes from supercritical CO2 extraction of organic hemp, short-path distillation, and using MCT oil as a base. This process removes unwanted components (chlorophyll, waxes) and concentrates cannabinoids. Ethanol extraction is cheaper but requires careful purification from solvent residues. Petrochemical extractions (hexane, butane) are cheap but pose a risk of product contamination.

Full-spectrum vs broad-spectrum vs CBG isolate

Full-spectrum CBG contains the full profile of cannabinoids and terpenes from the plant, including trace THC (below 0.3 percent). Broad-spectrum CBG is purified of THC but retains other cannabinoids and terpenes. CBG isolate is 99 percent pure cannabinoid, without other compounds. The price differences are small, but the differences in effect are significant.

A 2015 study showed that full-spectrum extracts with the same main cannabinoid content have stronger effects than isolates, precisely due to the entourage effect. The difference was 25-40 percent in anti-inflammatory models. Therefore, most users choose full or broad-spectrum. Isolates make sense mainly in clinical studies where it is necessary to isolate the effect of a specific molecule.

What are the side effects and contraindications for CBG?

CBG is generally well tolerated, with a safety profile similar to that of CBD. In an observational study of 127 CBG users, the most common side effects were dry mouth (16.5 percent), drowsiness (15 percent), and increased appetite (12 percent) (Cannabis and Cannabinoid Research, 2021). Serious adverse effects are rare and usually associated with very high doses.

Potential side effects of CBG include: dry mouth and eyes (due to modulation of the cholinergic system), slight lowering of blood pressure (at higher doses, through alpha-2), drowsiness or agitation (depending on dose and individual sensitivity), mild digestive disturbances (diarrhea, nausea in about 5 percent of users in observational studies).

Very rare side effects include: changes in appetite (both increase and decrease), headaches (in a small percentage of users), feelings of anxiety at very high doses (above 100 mg). Most side effects resolve after lowering the dose or are transient after a few days of regular use as the body adapts to the new cannabinoid.

Who should avoid CBG?

Absolute contraindications include: pregnancy and breastfeeding (lack of safety studies for the fetus and infant, potential for CBG to cross the placental barrier), severe liver diseases (CBG is metabolized by CYP450, risk of accumulation), children under 18 without medical supervision. All these groups require caution and medical consultation.

Relative contraindications include: patients with low blood pressure (hypotension may worsen), individuals with severe mental disorders (schizophrenia, bipolar disorder, CBG may modulate neurochemical balance), patients taking medications metabolized by CYP3A4 (see the interactions section above). In these groups, the decision to use CBG should be individualized.

Can CBG be safely used long-term?

There are no randomized placebo-controlled studies longer than 6 months for CBG in humans. Observational studies have included periods of up to 2 years and have not shown serious long-term side effects. However, this does not equate to full validation of safety. For any supplement, periodic breaks are recommended (e.g., 2 weeks every 3 months) and monitoring of health parameters.

Practical recommendation: use CBG for 8-12 weeks, then take a 2-week break and assess whether the effects have persisted. If not, return to supplementation. If so, consider whether further regularity is needed. This cyclical approach minimizes the risk of tolerance (although CBG does not exhibit classic tolerance like THC) and allows for assessing the real effectiveness of the cannabinoid.

In patients using CBG long-term, the following are monitored: liver function (ALT, AST, GGT every 6-12 months), blood pressure (at higher doses), body weight (CBG may increase appetite). Standard medical check-ups once a year cover most of these parameters, so additional visits are usually not necessary.

Frequently Asked Questions

What is CBG and how does it differ from CBD?

CBG (cannabigerol) is a non-psychoactive cannabinoid recognized as the mother of all cannabinoids because its acidic form, CBGA, is the biochemical precursor to CBDA, THCA, and CBCA. Unlike CBD, which primarily acts indirectly through the 5-HT1A receptor and FAAH inhibition, CBG binds directly to CB1 and CB2 as a partial agonist and activates the alpha-2 adrenergic receptor (Cascio et al., British Journal of Pharmacology, 2010). In a mature cannabis plant, the typical CBG content is less than 1 percent.

Does CBG have psychoactive effects?

No. CBG does not produce a high or intoxication effect because it behaves as a very weak partial agonist at the CB1 receptor and partially antagonizes the action of THC. The report WHO Expert Committee on Drug Dependence (41st session, 2018) confirms the safe profile of non-psychoactive cannabis cannabinoids. CBG does not affect driving or cause the tolerance typical of THC.

What is the dosage of CBG?

Preclinical and observational studies suggest a range of 10-50 mg of CBG per day for adults. A reasonable start is 10-15 mg once daily sublingually, titrating every 5-7 days by 10 mg. In an observational study, users reported benefits at an average dose of 25-30 mg daily (Cannabis and Cannabinoid Research, 2021). Higher doses (100-200 mg) were used in mouse models of IBD and are not routinely recommended for humans.

Does CBG help with glaucoma?

Potentially yes, provided it is used topically. The study by Colasanti (Journal of Ocular Pharmacology, 1990) showed that locally administered CBG lowers intraocular pressure in rabbits. The mechanism involves activation of the alpha-2 adrenergic receptor, the same one targeted by brimonidine drops. There is a lack of randomized trials in humans, so CBG does not replace any registered glaucoma therapy. Consultation with an ophthalmologist is mandatory.

Can CBG be combined with CBD?

Yes, and it is often beneficial. CBG and CBD act on partially complementary pathways: CBD modulates 5-HT1A and FAAH, while CBG activates CB1, CB2, and alpha-2. Russo's work in the British Journal of Pharmacology (PMC, BJP, 2011) described the entourage effect. In practice, broad-spectrum and full-spectrum oils naturally contain both compounds, in proportions dependent on the cannabis strain.

Is CBG legal in Poland?

Yes, CBG itself is not a controlled substance in Poland or the EU. The legality of the product depends on the THC content: CBG oils with THC below 0.3 percent comply with EU regulation 2021/2115 regarding hemp. Since 2019, EFSA has treated cannabinoid extracts as novel food, so CBG supplements require compliance with food regulations. Buy from trusted suppliers with COA certificates.

Does CBG have antibacterial effects?

Yes, and against resistant strains. The study by Farha et al. (ACS Infectious Diseases, 2020) showed that CBG inhibits the growth of methicillin-resistant Staphylococcus aureus (MRSA) at concentrations comparable to vancomycin in vitro. CBG disrupted bacterial biofilm and effectively acted in a mouse infection model. These data are preclinical; CBG does not replace antibiotics in treating bacterial infections in humans.

What do studies say about CBG in inflammatory bowel disease?

The work of Borrelli et al. (Biochemical Pharmacology, 2013) showed that CBG reduces inflammation in a mouse model of DNBS-induced colitis by about 50 percent compared to the control group. The mechanism involves inhibition of iNOS synthase, reduction of IL-1beta, and modulation of CB2. Observational data in humans suggest subjective improvement in IBS and IBD symptoms, but randomized trials in patients are still ongoing.

This article is for informational and educational purposes and does not constitute medical advice. Before starting to use cannabis or CBG for therapeutic purposes, consult your doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: September 27, 2025
Last update: April 23, 2026